Home » Stocks » Cogent Biosciences

Cogent Biosciences, Inc. (UMRX)

Oct 6, 2020 - Stock symbol was changed to COGT
Stock Price: $2.35 USD 0.00 (0.00%)
Updated Oct 5, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 99.80M
Revenue (ttm) 23.87M
Net Income (ttm) -23.11M
Shares Out 42.47M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 5, 2020
Last Price $2.35
Previous Close $2.35
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 2.32 - 2.41
Day's Volume 0
52-Week Range 0.30 - 3.72

More Stats

Market Cap 99.80M
Enterprise Value 82.45M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 42.47M
Float 17.04M
EPS (basic) -0.75
EPS (diluted) -0.86
FCF / Share -1.11
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 601,505
Short Ratio 0.85
Short % of Float 3.53%
Beta 1.31
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.18
PB Ratio 5.87
Revenue 23.87M
Operating Income -23.34M
Net Income -23.11M
Free Cash Flow -34.66M
Net Cash 17.35M
Net Cash / Share 0.41
Gross Margin -80.11%
Operating Margin -97.79%
Profit Margin -96.80%
FCF Margin -145.20%
ROA -25.76%
ROE -69.97%
ROIC -1,499.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0
What these ratings mean

Analyst Consensus: Buy

Price Target

$5.00*
(112.77% upside)
Low
4.00
Current: $2.35
High
6.00
Target: 5.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Income Statement | Balance Sheet | Cash Flow
Year20192018201720162015
Revenue22.509.738.366.362.99
Revenue Growth131.14%16.44%31.55%112.83%-
Gross Profit22.509.738.366.362.99
Operating Income-32.18-36.01-26.15-19.07-6.59
Net Income-31.83-34.53-25.49-18.12-6.59
Shares Outstanding30.4824.9010.1910.1910.19
Earnings Per Share-1.04-1.39-2.51-1.78-0.65
Operating Cash Flow-41.51-32.49-25.84-18.6417.72
Capital Expenditures0.17-0.55-0.91-3.31-1.99
Free Cash Flow-41.34-33.04-26.75-21.9515.72
Cash & Equivalents38.6879.8542.2969.76-
Total Debt6.03----
Net Cash / Debt32.6579.8542.2969.76-
Assets49.4285.9349.1275.55-
Liabilities17.6625.6920.8123.16-
Book Value31.7660.23-48.85-24.70-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cogent Biosciences, Inc.
Country United States
CEO Charles Wilson

Stock Information

Ticker Symbol UMRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: UMRX
IPO Date March 29, 2018

Description

Unum Therapeutics, a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a ?bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.